7 completed, 3 recruiting, 2 terminated, 1 unknown. 9 Not applicable, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 9 | Completed 5, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Benzodiazepine Dependence: new trials by email Literature Review of Benzodiazepine Dependence trials Research Report on Benzodiazepine Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence Baclofen 30 mg, Baclofen 60 mg, Placebo - Benzodiazepine Dependence | Phase 2 / Phase 3 | Recruiting | Hospices Civils de Lyon | 93 | 2026-01-15 | 2026-05-11 |
| Anxiety Lowering and Deprescribing Through Emotion Regulation ALDER - Benzodiazepine Dependence, Anxiety Disorders | Not applicable | Completed | Northwestern University | 33 | 2024-05-16 | 2025-12-16 |
| Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study Benzodiazepine Adverse Reaction, Depression, Anxiety | Recruiting | The First Affiliated Hospital of Dalian Medical University | 100 | 2024-02-11 | 2025-04-11 | |
| Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly GP - pharmacist collaboration and pharmacist motivational interviewing - Primary Care, Health Plan Implementation | Not applicable | Recruiting | Nantes University Hospital | 400 | 2023-10-16 | 2026-06-24 |
| Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention EMPOWER-ED - Taking Benzodiazepines for Any Reason for 3 Months, Benzodiazepine Dependence | Not applicable | Completed | VA Office of Research and Development | 170 | 2022-06-01 | 2026-01-23 |
| Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT Oxytocin nasal spray, Saline (NaCl 0,9 %) (placebo) - Benzodiazepine Dependence | Phase 2 | Completed | St. Olavs Hospital | 66 | 2022-03-01 | 2026-09-28 |
| Prevention of Benzodiazepine Misuse in Primary Care Educational intervention with prescription feedback, Information on treatment guidelines - Benzodiazepine Dependence, Benzodiazepine Abuse | Not applicable | Withdrawn | Karolinska Institutet | 2020-09-01 | 2023-02-23 | |
| The Effect of Self-Forgiveness on Self-Stigma in Addiction. Six Step Model of Self-Forgiveness, Treatment as Usual (TAU) - Substance Use Disorders, Opiate Dependence | Not applicable | Completed | University of Pittsburgh | 130 | 2019-08-01 | 2021-09-05 |
| Blended Care for the Discontinuation of Benzodiazepine Use Blended care, Usual care - Benzodiazepine Dependence, Benzodiazepine Dependent | Not applicable | Completed | Kristien Coteur | 924 | 2019-06-24 | 2022-07-15 |
| Electronic Deprescribing Tool for the Prevention of PIP Electronic Deprescribing tool - Prevention, Benzodiazepine Dependence | Not applicable | Terminated | University of Beira Interior | 280 | 2017-10-02 | 2021-04-30 |
| Electroacupuncture for Tapering Off Long-term Benzodiazepine Use Electroacupuncture, Placebo acupuncture - Benzodiazepine Dependence | Not applicable | Unknown | The University of Hong Kong | 144 | 2015-07-01 | 2017-06-15 |
| Effectiveness of Mindfulness Based Relapse Prevention for Chronic Users of Benzodiazepines Mindfulness-Based Relapse Prevention - Benzodiazepine Dependence | Not applicable | Completed | Federal University of São Paulo | 76 | 2013-10-01 | 2017-05-09 |
| Gabapentin Treatment of Benzodiazepine Dependence gabapentin, Placebo - Benzodiazepine Dependence | Phase 2 | Terminated | New York State Psychiatric Institute | 2 | 2013-07-01 | 2019-04-24 |
| Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients Gabapentin, Placebo - Benzodiazepine Dependence, Opioid Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 19 | 2007-01-01 | 2019-04-24 |
Anxiety Disorders (4) · Behavior, Addictive (2) · Opioid-Related Disorders (2) · Substance-Related Disorders (2) · Alcoholism (1) · Cocaine-Related Disorders (1) · Depression (1) · Heroin Dependence (1) · Long Term Adverse Effects (1) · Parasomnias (1) · Sleep Initiation and Maintenance Disorders (1)
Mental Disorders (7) · Behavior (3) · Chemically-Induced Disorders (3) · Compulsive Behavior (2) · Impulsive Behavior (2) · Narcotic-Related Disorders (2) · Nervous System Diseases (2) · Sleep Wake Disorders (2) · Alcohol-Related Disorders (1) · Behavioral Symptoms (1) · Dyssomnias (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Sleep Disorders, Intrinsic (1) · Substance-Related Disorders (1)
Gabapentin (2) · Baclofen (1) · Electroacupuncture (1) · Oxytocin (1) · Sodium Chloride (1) · Therapeutics (1)
New York State Psychiatric Institute (2) · Federal University of São Paulo (1) · Hospices Civils de Lyon (1) · Karolinska Institutet (1) · Kristien Coteur (1) · Nantes University Hospital (1) · Northwestern University (1) · St. Olavs Hospital (1) · The First Affiliated Hospital of Dalian Medical University (1) · The University of Hong Kong (1) · University of Beira Interior (1) · University of Pittsburgh (1) · VA Office of Research and Development (1)
United States (5) · China (2) · France (2) · Belgium (1) · Brazil (1) · Norway (1) · Portugal (1) · Sweden (1)
Ana R Noto, PhD (1) · Elizabeth Addington, PhD (1) · Holly P Branthoover, EdD. (1) · Johan Franck, MD, PhD (1) · John J Mariani, M.D (1) · John J. Mariani, MD (1) · Keith N. Humphreys, PhD MA (1) · Michael A Cucciare, PhD (1) · Michael P Verona, MA (1) · Olav Spigset, MD, PhD (1) · Tone Aurora Pleym, MD, PhD-candidate (1)
PMID 26962719, PMID 28359309, PMID 30504097, PMID 32075832, PMID 34013489, PMID 36111174, PMID 36121697, PMID 36413221, PMID 37027198, PMID 37711743, PMID 41533380
2019 (1), K23DA021209 (1)